ORIONS Money Stocks

[ADVFN_bioking]

CYTR = MC$16 M -GREAT NEWS OUT by drug partner Orphazyme..still trading UNDER Cash balance

Orphazyme announces US Early Access Program for Niemann-Pick disease Type C
https://www.globenewswire.com/news-release/2020/01/06/1966421/0/en/Orphazyme-announces-US-Early-Access-Program-for-Niemann-Pick-disease-Type-C.html

The EAP provides a pathway for patients with serious, life-threatening diseases or conditions who lack therapeutic alternatives to gain access to investigational drugs before they are approved.

Kim Stratton, Chief Executive Officer, commented, “Orphazyme is deeply committed to providing access to new therapies for people living with rare diseases such as NPC. There are currently no approved products to treat NPC in the US and we are pleased to make arimoclomol, a potential first-in-class innovative oral therapy, available pre-commercially to US patients through this program. We plan to file for approval of arimoclomol in the US in H1 2020”.


CYTR thread for more infos about the stock
https://investorshub.advfn.com/CytRx-Corp-CYTR-3392/